The above scenario is a rare case where the use of M immunoglobulin was used to control a mycobacterium vaccae outbreak. This mycobacterium is a type of staphylococcus aureus (S. aureus). A study was conducted to see if M immunoglobulin would indeed have an effect on S. aureus. In this study, ten persons with invasive staph infections were treated with M immunoglobulin and their staph infections were monitored over a three-month period mycobacterium vaccae supplement. The results showed no increase in S. aureus contamination from those patients who received M immunoglobulin compared to those who received placebo.
The other study was conducted using M quercetris edil rk, CFID fusion, and M vaccine complex and N q10 toxicity was used. In this study, no toxicity was noted in the animals in this study counsellor. However, there was one case wherein one of the subjects in this study tested positive for CFIDS and was diagnosed with CFIDS-related serotonin syndrome.
The last study utilized M quercetris antibacterial activity against L. inosantesis. A mycobacterium was identified as the causative agent of this condition. This particular mycobacterium has been shown to be resistant to quercetin antibacterial activity. Hence, it was not effective against L. Inosanto is. The lack of activity against this species may explain why quercetin antibacterial agents are not effective in the treatment of this condition.
Overall, these studies provide additional insight into the mycobacterium and CFIDS relationship. One noteworthy finding was the consistent observation that the mycobacterium was resistant to a wide range of antibacterial agents. However, various agents proved to have minimal effect on this species. These findings are important in the quest for a treatment for CFIDS.
Other potential factors that affect CFIDS include infections by other enteric pathogens, such as staph, hepatitis B, or chlamydia, as well as exposure to toxins (e.g., organophosphate pesticide). Mycobacteriumaque organisms can also generate toxins within the body, which can affect CFIDS patients. The identification of factors that trigger an attack is an important first step in designing an effective CFIDS treatment regimen.
CFIDS, or chronic fatigue syndrome, affects an estimated 10% of the global population. Because of the complexity of the pathophysiology and the multiple potential factors that could initiate symptoms, many physicians do not consider it a life-threatening condition. Treating CFIDS is a challenge for physicians, because of the uncertain clinical presentation and the paucity of existing medications. The Food and Drug Administration (FDA) has approved two medications to date that are indicated for the treatment of CFIDS Chandraxin and X-rayresonator. Nocegmentum, a quinolone derivative, is not approved for use in patients with CFIDS.